Button 0Button 1Button 2Button 3

References

For Figure 1, Chromosomal hot spots, and Master Table 1a: review profile.


1. Alers JC, Rochat J, Krijtenburg P-J, et al. Identification of genetic markers for prostatic cancer progression. Laboratory Investigation 2000: 80(6): 931-942
2. Cher ML, MacGrogan D, Bookstein R, et al. Comparative genomic hybridization, allelic imbalance, and fluorescence In Situ hybridization on chromosome 8 in prostate cancer. Genes, Chromosomes and Cancer 1994: 11:153-162
3. Cher ML, Bova S, Moore DH, et al. Genetic alterations in untreated metastases and Androgren-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Research 1996: 56: 3091-3102
4. Kofler K, Erdel M, Utermann G, et al. Molecular genetics and structural genomics of the human protein kinase C gene module. Genome Biology 2002: 3(3): research0014.1-0014.10
5. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001. 412:822-826
6. Xin W, Rhodes DR, Ingold C et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. American Journal of Pathology 2003: 162(1); 255-261
7. Nupponen NN, Kakkola L, Koivisto P, et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. American Journal of Pathology 1998: 153 (1): 141-148
8. Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. The Journal of Urology 2001: 166: 2171-2177
9. Vastag B. Genome Analysis Yields Mutations linked to Hereditary Prostate Cancer. Science (Medical News and Perspectives) 2002: 287(7): 20
10. Cunningham JM, Shan A, Wick MJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Research 1996: 56: 4475-4482
11. Luo, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia; Molecular dissection by gene expression profiling. Cancer research 2001: 61: 4683-4688
12. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer research 2001: 61:5974-5978
13. Bubendorf L, Kononen J, Koivisto P. ŒSurvey of gene amplifications during prostate cancer progression by high throughput fluorescence in situ hybridization on tissue microarrays. Cancer Research 1999: 59:803-806
14. Dash A, Maine IP, Varambally S et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. American Journal of Pathology 2002: 161(5):1743-1748
15. Kalts-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Laboratory investigation 2000: 80: 1455- 1464
16. Jenkins R, Takahashi S, DeLacey K, et al. Prognostic Significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in Stage T3N0M0 Prostate Cancer. Genes, Chromosomes and Cancer 1998: 21:131-143
17. Emmert-Buck MR, Vocke CD, Pozzatti RO, et al. Allelic loss on Chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Research 1995: 55:2959-2962
18. Seelan RS, Qian C, Yokomizo A, et al. Human ceramidase is overexpressed but not mutated in prostate cancer. Genes, Chromosomes and Cancer, online .
19. Bova GS, Carter BS, Bussemakers MJG, et al. Homozygous deletion and frequent allelic loss of chomosome 8p22 loci in human prostate cancer. Cancer Research 1993: 53:3869-3873
20. Park DJ, Wilczynski SP, Pham EY. Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol 157(5);1995-9. 21. Wolter H, Trijic D, Gottfried HW, Mattfeldt T. Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol 2002: 41(3):328-34
22. Wolter H, Gottfried HW, Mattfeldt T. Genetic changers in stage pT2N0 prostate cancer studied by comparitive genomic hybridization. BJU international 2002: 89: 310-316
23. Stravodimos K, Constantinides C, Manousakas T, et al. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. Anticancer Res 2000: 20(5C):3823-8
24. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protoconogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Research 1992: 52: 6940-6944
25. Carter BS, Ewing CM, Ward SW et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990: 87:8751-8755
26. Gorgoulis VG, Tiniakos DG, Mariatos G et al, Recent advances in early prostatic cancer, Anticancer Research 1999: 19:2327-2348
27. Bussemakers MJG, Bokhoven van A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in Prostate Cancer. Cancer Research 1999: 59: 5957-5979
28. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997: 275:1943-1947
29. Vlietstra RJ, van Alewijk DCJ, Hermans KGL, et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Research 1998: 58: 2720-2723
30. Li D-M, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by a transforming growth factor _1. Cancer Research 1997: 57: 2124-2129
31. Vocke CD, Pozzatti RO, Bostwick DG, et al. Analysis of 99 microdissected prostatic carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Research 1996: 56: 2411-2416
32. Bookstein R, Rio P, Madraperla SA, et al. Promoter deletion and loss of Retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990: 87: 7762-7766
33. Afonso A, Emmert-Buck MR, Duray PH, et al. Loss of Heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. The Journal of Urology 1999: 162: 922-926
34. Bangma CH, Nasu Y, Ren C. Metastasis-related genes in prostate cancer. Seminars in Oncology 1999: 26(4): 422-427
35. Eastham JA, Stapleton AMF, Gousse AE et al. Association of p53 mutations with metastic prostate cancer. Clinical cancer research 1995: 1: 1111-1118
36. Stapleton AMF, Timme TL, Gousse AE et al. Primary human prostate cancer cells harbouring p53 mutations are clonally expanded in metastases. Clinical cancer research 1997: 3:1389-1397
37. Colombel M, Symmans F, Gil S, et al. Detection of the Apoptosis-Suppressing Oncoprotein bcl-2 in Hormone refractory human prostate cancers. American Journal of Pathology 1993: 143(8):390-400
38. Shabaik AS, Krajewski S, Burgan A et al. Bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 1995: 3:17-27
39. Fujiwara Y, Emi M, Ohata H, et al. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Research 1993: 53: 1172-1174
40. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer research 2001: 61: 5692-5696
41. Yousef GM, Luo L-Y, Diamandis EP et al. Identification of novel human kalikrein-like genes on chromosome 19q13.3-q13.4. Anticancer research 1999: 19:2843-2852
42. Stephenson S, Verity K, Ashworth LK, et al. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kalikrein gene family cluster of chromosome 19q13.3-q13.4. Journal of Biological Chemistry 1999: 274(33): 23210-23214
43. Diamandis EP, Yousef GM, Luo LY, et al. The new human kalikrein gene family; implications in carcinogenesis. Trends Endocrinol Metab 2000: 1:54-60
44. Liu XL, Wazer DE, Watanabe K, et al. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer research 1996: 56; 3371-3379
45. Anisowicz A, Sotiropoulou G, Stenman G, et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol med 1996: 2: 624-636
46. Little SP, Dixon EP, Norris F, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer¹s disease brain. J Biol Chem 1997: 272: 25135-25142
47. Yamashiro K, Tsuruoka N, Kodama S, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acat 1997: 1350:11-14
48. Yousef GM, Scorilas A, Chang A, et al. Down-regulation of the human kalikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002: 51(2):126-132
49. Hooper JD, Bui LT, Rae FK, et al. Identification and characterization of KLK14, a novel kalikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001: 73(1):117-122
50. Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad, Sci 1997: 94: 3320-3323
51. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995: 9: 401-406
52. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992: 89: 6319-6323
53. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002: 30(2):181-4
54. Skacel M, Ormsby AH, Pettay JD, et al. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 2001: 32(12): 1392-7
55. Rao UN, Gollin SM, Beaves S, et al. Comparative genomic hybridization of hepatocellular carcinoma: correlation with fluorescence in situ hybridization in paraffin-embedded tissue. Mol Diagn 2001: 6(1):27-37
56. Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002: 15(1):35-44
57. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, et al. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 2001:12:20(31):4169-79,
58. Oxley JD, Winkler MH, Gillatt DA, et al. Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 2002: 55(2):118-20
59. Liu HL, Gandour-Edwards R, Lara PN Jr, et al. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001: 7(5):372-4
60. Savinainen KJ, Saramaki OR, Linja MJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002: 160(1):339-45
61. Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002: 3:1662-70

62. Burger MJ, Tebay MA, Keith PA et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. International Journal of Cancer 2002: 100: 228-237


  • Infrastructure and Technology overview
  • Literature Selection criteria
  • Glossary
  • References
  • Figure 1: Chromosomal hot spots
  • Master Table 1a: Review Profile

    		•

    © Copyright 2004 : St George Urology Research